Granules India growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+19.7%−0.5%−0.1%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+25.4%+10.4%−6.3%
+23.5%+11.0%−11.1%
+18.6%+23.7%−21.5%
+18.3%+23.7%−20.5%
+23.5%+13.3%+12.6%
+36.9%+15.2%+13.8%
−8.5%+97.2%−40.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GRANULES₹837.35

Granules India Ltd.

· Pharma & Health
₹ CrorePeersAUROPHARMAIPCALABAARTIDRUGSERISINDGNEMCUREJUBLPHARMACONCORDBIOMcap ₹20,750 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-0.1-0.5+19.7—
EBITDA Growth—-6.3+10.4+25.4—
EBIT Growth—-11.1+11.0+23.5—
Net Income Growth—-21.5+23.7+18.6—
EPS Growth—-20.5+23.7+18.3—
Total Assets Growth—+12.6+13.3+23.5—
Total Equity Growth—+13.8+15.2+36.9—
Cash from Operations Growth—-40.5+97.2-8.5—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.